LDC provides biopharmaceutical companies with access to high-quality pharmaceutical leads and therapeutic antibodies based on the most innovative findings from leading research institutions. All leads come with proof-of-concept in animal models, solid IP protection and comprehensive data packages, enabling a seamless transition into a company portfolio. Industry partners have the option to stay in contact with LDC and academic partners, consulting and collaborating with them whenever needed and appropriate.



Successful de-risking

From the initial project selection and throughout the drug discovery process, LDC applies stringent go/no-go criteria, making sure that resulting leads have an above-average prospect of success.

Portfolio information

120 Projects started
23 Industry deals (option/licence/co-development/spin-outs/subsidiary companies)
30 Projects actively pursued
17 Projects stopped for scientific reasons
> 300 Suggestions for new projects from our academic network


Flexible partnership structure

Depending on your needs and strategic focus we build various forms of alliances and deals including:

  • Option deals
  • Co-development or collaboration agreements
  • Licence agreements
  • Strategic partnerships
  • Incubation and financing of early project ideas at LDC
  • Spin-offs
Your benefits
  • Gain access to highly innovative first/best-in-class therapy approaches
  • Take on viable leads with preclinical proof-of-concept
  • Get involved early
  • Work with a team that speaks your language and understands industry requirements
  • Expand your network to include excellent scientists and their research organizations
  • Filter project ideas, including validation or de-validation